FDA, Protein Expression and Protein Production

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

FDA

Protein Expression

Protein Production

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

DECEMBER 3, 2020

protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 .–( BUSINESS WIRE )– Stoke Therapeutics , Inc.

Clinical Trials

Clinical Trials Protein Expression Pharmacokinetics Trials

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

The Pharma Data

JANUARY 13, 2021

However, before the Phase III program may begin, the FDA requested a meeting with Theratechnologies to discuss questions and comments received on certain aspects of the proposed trial design, to ensure alignment with the agency’s expectations with NASH trials. Vivity received FDA approval in February 2020. Mogrify – U.K.-based

Licensing

Licensing Licensing Clinical Trials Trials

Drug Discovery Digest

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

Stay Connected